Abstract: Provided are isolated monoclonal antibodies or any antigen-binding fragment thereof which bind to hepatitis C virus E2 protein (HCV E2). In particular the presently claimed subject matter concerns neutralizing anti HCV E2 antibodies, and their use for treating HCV infection. Furthermore, the presently claimed subject matter concerns methods for preparing neutralizing anti HCV scFv antibodies associated with HCV clearance.

Abstract: The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.

Abstract: The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.

Abstract: The present invention provides novel recombinant protein and peptide inhibitors of NS3 serine protease of the hepatitis C virus (HCV). The invention discloses analogs, fragments and derivatives of the identified inhibitors, nucleic acids encoding same, and methods of use thereof for the treatment of HCV infection. The invention further provides novel constructs and methods for the screening of protease inhibitors in vivo, using a recombinant engineered reporter protein that is cleavable by a protease, co-expressed with the recombinant protease in bacteria.